Retatrutide has been studied for both weight and blood-glucose outcomes. Those are related but different endpoints. A phase 2 trial in people with type 2 diabetes is useful because it reports each outcome with its own time point and comparison group.
Who took part?
The trial randomized 281 participants across 42 US centres; 275 were included in efficacy analyses. It used placebo and dulaglutide as comparators. The primary endpoint was the change in HbA1c at 24 weeks. HbA1c is a measure used to assess longer-term blood-glucose levels.
What changed, and by how much?
In the 12 mg maintenance-dose group, the least-squares mean HbA1c change at 24 weeks was -2.02 percentage points, compared with -0.01 with placebo and -1.41 with dulaglutide. At 36 weeks, body-weight change in that retatrutide group was -16.94%, compared with -3.00% with placebo. These values refer to one trial group, not every participant or every retatrutide study.
Do not mix the two kinds of percentage
An HbA1c change from 8% to 6% is a decrease of 2 percentage points. It is a 25% relative reduction from the starting value. By contrast, a body-weight change is usually reported relative to starting weight. Mixing those expressions changes what a result appears to mean.
The benefit figures need their safety context
Gastrointestinal adverse events occurred in 35% of participants across retatrutide groups, versus 13% with placebo. Most were mild or moderate. Phase 2 findings do not settle long-term safety or establish that research-catalogue material is equivalent to the trial formulation. The doses identify study groups; they are not use instructions. For laboratory procurement, confirm material identity and documentation independently of the clinical results.
Related materials and next steps
Explore the NHD catalogue records for Retatrutide. Confirm the required molecular form, quantity and lot-document availability before relying on a listing for procurement. A catalogue record does not establish equivalence to a published study material.
Send the product or sequence, quantity and document requirements. For more background, browse the analytical methods guides and research glossary.
Sources and reading scope
Source links checked 5 October 2026. Research summaries use the accessible original abstract unless a full-text source is explicitly identified. Guidance documents and external supplier explanations are technical references, not NHD batch evidence or a claim of regulatory compliance. Any example introduced as hypothetical or teaching is a calculation, not a measured product result.
NHD catalogue materials are for qualified laboratory research, development and manufacturing enquiries. This article does not provide instructions for human or veterinary use.
Sources & editorial method
AI-assisted writing and source checks; conceptual illustrated cover.
1 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Study results and labeled examples are separated. Original-source, arithmetic, readability and internal-link checks; no independent human peer review recorded.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- Original phase 2 retatrutide trial in type 2 diabetesChecked 2026-10-05; source scope is identified in the article.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
